> top > projects > sentences > docs > PubMed:24993594 > annotations
sentences Home  

PubMed:24993594 JSONTXT 6 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-138 Sentence denotes Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
T1 0-138 Sentence denotes Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
TextSentencer_T2 139-152 Sentence denotes INTRODUCTION:
T2 139-152 Sentence denotes INTRODUCTION:
TextSentencer_T3 153-297 Sentence denotes Folate receptor-α regulates cellular uptake of folates and antifolates (eg, pemetrexed) and is frequently expressed in pulmonary adenocarcinoma.
T3 153-297 Sentence denotes Folate receptor-α regulates cellular uptake of folates and antifolates (eg, pemetrexed) and is frequently expressed in pulmonary adenocarcinoma.
TextSentencer_T4 298-349 Sentence denotes EGFR is an established therapeutic target in NSCLC.
T4 298-349 Sentence denotes EGFR is an established therapeutic target in NSCLC.
TextSentencer_T5 350-396 Sentence denotes Therapies targeting FRA or EGFR are available.
T5 350-396 Sentence denotes Therapies targeting FRA or EGFR are available.
TextSentencer_T6 397-485 Sentence denotes The association between FRA and EGFR expression in advanced NSCLC has not been explored.
T6 397-485 Sentence denotes The association between FRA and EGFR expression in advanced NSCLC has not been explored.
TextSentencer_T7 486-620 Sentence denotes Combining therapeutic FRA antibodies with an EGFR inhibitor might be beneficial, if both of the targets are significantly coexpressed.
T7 486-620 Sentence denotes Combining therapeutic FRA antibodies with an EGFR inhibitor might be beneficial, if both of the targets are significantly coexpressed.
TextSentencer_T8 621-642 Sentence denotes PATIENTS AND METHODS:
T8 621-642 Sentence denotes PATIENTS AND METHODS:
TextSentencer_T9 643-839 Sentence denotes Specimens from 160 advanced NSCLC patients receiving pemetrexed-based chemotherapy were assessed for membranous FRA and EGFR protein expression using immunohistochemistry and the Hybrid (H)-score.
T9 643-839 Sentence denotes Specimens from 160 advanced NSCLC patients receiving pemetrexed-based chemotherapy were assessed for membranous FRA and EGFR protein expression using immunohistochemistry and the Hybrid (H)-score.
TextSentencer_T10 840-941 Sentence denotes EGFR (exons 18-21) and Kirsten RNA-associated rat sarcoma 2 virus (exon 2) mutations were determined.
T10 840-941 Sentence denotes EGFR (exons 18-21) and Kirsten RNA-associated rat sarcoma 2 virus (exon 2) mutations were determined.
TextSentencer_T11 942-1064 Sentence denotes Results were correlated to patients' clinicopathological data, progression-free survival (PFS), and overall survival (OS).
T11 942-1064 Sentence denotes Results were correlated to patients' clinicopathological data, progression-free survival (PFS), and overall survival (OS).
TextSentencer_T12 1065-1073 Sentence denotes RESULTS:
T12 1065-1073 Sentence denotes RESULTS:
TextSentencer_T13 1074-1242 Sentence denotes Forty-seven patients (29%) had tumors with strong FRA and EGFR expression, but no statistically significant correlation was seen between protein levels of FRA and EGFR.
T13 1074-1242 Sentence denotes Forty-seven patients (29%) had tumors with strong FRA and EGFR expression, but no statistically significant correlation was seen between protein levels of FRA and EGFR.
TextSentencer_T14 1243-1443 Sentence denotes High membranous FRA expression (H-score ≥ 20) was associated with prolonged PFS (5.5 vs. 3.4 months; hazard ratio [HR], 0.6060; P = .0254) and improved OS (12.1 vs. 6.4 months; HR, 0.5726; P = .0076).
T14 1243-1443 Sentence denotes High membranous FRA expression (H-score ≥ 20) was associated with prolonged PFS (5.5 vs. 3.4 months; hazard ratio [HR], 0.6060; P = .0254) and improved OS (12.1 vs. 6.4 months; HR, 0.5726; P = .0076).
TextSentencer_T15 1444-1455 Sentence denotes CONCLUSION:
T15 1444-1455 Sentence denotes CONCLUSION:
TextSentencer_T16 1456-1553 Sentence denotes Survival times are improved in NSCLC patients whose tumors show strong membranous FRA expression.
T16 1456-1553 Sentence denotes Survival times are improved in NSCLC patients whose tumors show strong membranous FRA expression.
TextSentencer_T17 1554-1783 Sentence denotes No statistical correlation between membranous FRA and EGFR expression was demonstrated in advanced NSCLC, but 47 patients (29%) had higher expression of both of the receptors and could be suitable for combined targeted therapies.
T17 1554-1783 Sentence denotes No statistical correlation between membranous FRA and EGFR expression was demonstrated in advanced NSCLC, but 47 patients (29%) had higher expression of both of the receptors and could be suitable for combined targeted therapies.